TRUNC Trial Evaluates the Stentys Xposition S for Unprotected Left Main CAD

July 19, 2016—Stentys announced that it has commenced enrolling patients in the TRUNC trial to evaluate the long-term safety and efficacy of the company’s Xposition S sirolimus-eluting self-apposing stent to treat unprotected left main coronary artery disease.

The first implantation was performed at Treant Hospital in Emmen, the Netherlands. In the company’s press release, Rutger Anthonio, MD, and Gillian Jessurun, MD, commented, “The procedure went very smoothly. The Xposition S stent is perfectly suited for the treatment of left main lesions because it guarantees excellent apposition in a vessel segment with substantial diameter variation. In addition, the stent allows easy access to any anatomical side branch without the need to perform kissing balloon inflation, which minimizes overall manipulation.” 

In March 2016, Stentys announced that the Xposition S received European CE Mark approval for this indication. The initial CE Mark approval for the device was announced in April 2015.